Archives
Upcoming Events
- ESC Congress 2019 August 31, 2019
- ESC Congress 2019 September 1, 2019
- ESC Congress 2019 September 2, 2019
Follow us on Twitter
My Tweets
Category Archives: Central and Eastern Europe
VisCardia Announces First Implant of the VisONE® System for Treating Heart Failure
Below, we are re-publishing with permission the press-release issued by VisCardia Inc. on the 1st of August 2018 PORTLAND, Ore.–VisCardia Inc., a privately held medical device developer, announced today the first implant of the VisONE® implantable system for heart failure, and … Continue reading
FDA inspections produce solid evidence of high quality clinical trial data originating in Central and Eastern Europe
Clinical Accelerator is a clinical CRO with a special focus on Central and Eastern Europe currently operating in 11 countries of that region: Bulgaria, Estonia, Georgia, Hungary, Latvia, Lithuania, Moldova, Poland, Romania, Russian Federation, and the Ukraine (listed alphabetically). The … Continue reading
ARREST Phase IIb Top-Line 52 weeks results
Below, we are re-publishing with permission the press-release issued by Galmed Pharmaceuticals Ltd. on the 12th of June 2018 Galmed’s 600 mg Aramchol™ Achieved a Regulatory Approvable Endpoint Showing NASH Resolution Without Worsening of Fibrosis, in NASH Patients, in the Global … Continue reading
Replicor discloses long term functional control of HBV and HDV infection in high proportions of treated patients at EASL 2018
Below, we are re-publishing with permission the press-release issued by Replicor on the 13th of April 2018 MONTREAL, April 13, 2018 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic … Continue reading
Clinical Accelerator announces collaboration with VisCardia for investigating a novel device therapy for chronic heart failure
Kiev, Ukraine – December 11, 2017: Clinical Accelerator, a full-service clinical contract research organization, is pleased to announce it has entered into a collaboration with VisCardia Inc. for conducting clinical studies for its VisONE medical device in the Ukraine. The … Continue reading
Promising Interim Clinical Data for NOX66
Below, we are re-publishing with permission the press-release issued by Noxopharm Limited on the 20th of November 2017 PROMISING INTERIM CLINICAL DATA FOR NOX66 Patients with metastatic, late-stage cancers 10 of 11 patients showing no disease progression following 3-months treatment with NOX66 … Continue reading
REPLICOR’S NEW PHASE II TRIAL CONDUCTED BY CLINICAL ACCELERATOR PRODUCES EXCITING CLINICAL DATA FOR THEIR NUCLEIC ACID POLYMER (NAP) DRUG REP 2139-CA FOR PATIENTS WITH HBV / HDV CO-INFECTION.
In December last year a Clinical Accelerator post (1) reported that recruitment was underway in Moldova for an interesting Phase II trial of Replicor’s novel nucleic acid polymer (NAP), REP 2139-Ca, in combination with the immunotherapeutic agent, pegylated interferon alfa-2a … Continue reading
